Ann: Novogen Presents at Biotech Showcase Conference, page-7

Yep, I'm in favour of partnerships for stage 3 trials. It stops the cash drain on investors money and allows big pharma to study the data in real time. That leaves a greater chance of market capitalisation increasing and a buy-out or merger offer. We will only lose if we go lone ranger all the way to a commercial product. Our product might be out of patent by the time we can convince the US government to buy it.

Big pharma have large lobby budgets and politicians have their conflicts of interest, umm I mean shareholdings.